WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: NYSE:WX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $45.00
- 200 Day Moving Avg: $43.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 25.93
- P/E Growth: 0
Frequently Asked Questions for WuXi PharmaTech (Cayman) (NYSE:WX)
What is WuXi PharmaTech (Cayman)'s stock symbol?
WuXi PharmaTech (Cayman) trades on the New York Stock Exchange (NYSE) under the ticker symbol "WX."
How were WuXi PharmaTech (Cayman)'s earnings last quarter?
WuXi PharmaTech (Cayman) Inc. (NYSE:WX) announced its quarterly earnings data on Tuesday, November, 3rd. The company reported $0.31 EPS for the quarter, meeting the Zacks' consensus estimate of $0.31. The firm earned $213.60 million during the quarter, compared to the consensus estimate of $205.24 million. The firm's quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.54 earnings per share. View WuXi PharmaTech (Cayman)'s Earnings History.
Who are some of WuXi PharmaTech (Cayman)'s key competitors?
Some companies that are related to WuXi PharmaTech (Cayman) include DexCom (DXCM), Icon Plc (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), VWR Corp (VWR), Bruker (BRKR), Alere (ALR), PAREXEL International (PRXL), EXACT Sciences (EXAS), Accelerate Diagnostics (AXDX), Abaxis (ABAX), Genomic Health (GHDX), Analogic (ALOG), BioTelemetry (BEAT), Heska Corp (HSKA), China Cord Blood Corp (CO), NeoGenomics (NEO) and Natera (NTRA).
How do I buy WuXi PharmaTech (Cayman) stock?
Shares of WuXi PharmaTech (Cayman) can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of WuXi PharmaTech (Cayman) stock cost?
One share of WuXi PharmaTech (Cayman) stock can currently be purchased for approximately $45.90.
Consensus Ratings for WuXi PharmaTech (Cayman) (NYSE:WX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for WuXi PharmaTech (Cayman) (NYSE:WX)
(Data available from 5/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/5/2015||Morgan Stanley||Downgrade||Overweight -> Equal Weight||N/A|
|8/14/2015||William Blair||Reiterated Rating||Outperform -> Buy||N/A|
Earnings History for WuXi PharmaTech (Cayman) (NYSE:WX)Earnings History by Quarter for WuXi PharmaTech (Cayman) (NYSE:WX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/3/2015||Q3||$0.31||$0.31||$205.24 million||$213.60 million||View||N/A|
|8/13/2015||Q215||$0.39||$0.38||$195.26 million||$194.14 million||View||Listen|
|5/13/2015||Q1||$0.32||$0.36||$174.29 million||$180.00 million||View||Listen|
|3/5/2015||Q414||$0.53||$0.55||$189.54 million||$190.60 million||View||Listen|
|11/12/2014||Q314||$0.48||$0.54||$172.60 million||$173.60 million||View||Listen|
|8/13/2014||Q214||$0.47||$0.49||$162.11 million||$163.40 million||View||Listen|
|5/14/2014||Q114||$0.39||$0.30||$145.00 million||$146.70 million||View||Listen|
|3/5/2014||Q413||$0.43||$0.53||$155.76 million||$157.10 million||View||N/A|
|11/13/2013||Q313||$0.39||$0.47||$145.29 million||$146.70 million||View||Listen|
|8/12/2013||Q2 2013||$0.39||$0.46||$141.10 million||$142.33 million||View||N/A|
|5/13/2013||Q1 2013||$0.32||$0.35||$130.02 million||$131.90 million||View||Listen|
|3/7/2013||Q4 2012||$0.30||$0.38||$123.71 million||$125.70 million||View||Listen|
|11/12/2012||Q312||$0.30||$0.36||$123.17 million||$125.84 million||View||N/A|
Earnings Estimates for WuXi PharmaTech (Cayman) (NYSE:WX)
Current Year EPS Consensus Estimate: $1.51 EPS
Next Year EPS Consensus Estimate: $1.77 EPS
Dividend History for WuXi PharmaTech (Cayman) (NYSE:WX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for WuXi PharmaTech (Cayman) (NYSE:WX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for WuXi PharmaTech (Cayman) (NYSE:WX)
Latest Headlines for WuXi PharmaTech (Cayman) (NYSE:WX)
WuXi PharmaTech (Cayman) (WX) Chart for Thursday, May, 25, 2017